Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30135193 | 0.91 | L3MBTL1 (0.52) | TRPA1TSHRL3MBTL1MAPK1TDP1 | |
| SCHEMBL17571407 | 0.88 | TSHR (0.56) | TRPA1TSHRL3MBTL1MAPK1TDP1 | |
| SCHEMBL2669321 | 0.80 | AAK1 (0.47) | TRPA1TSHRL3MBTL1MAPK1TDP1 | |
| SCHEMBL28041 | 0.78 | PTK2 (0.61) | TRPA1TSHRL3MBTL1MAPK1TDP1 | |
| SCHEMBL14497054 | 0.77 | TRPA1 (0.47) | TRPA1TSHRL3MBTL1MAPK1TDP1 | |
| SCHEMBL5543004 | 0.77 | TRPA1 (0.47) | TRPA1TSHRL3MBTL1MAPK1TDP1 | |
| SCHEMBL2669303 | 0.75 | L3MBTL1 (0.53) | TSHRL3MBTL1MAPK1TDP1PTK2 | |
| SCHEMBL30135218 | 0.75 | SCN9A (0.43) | KDM4EALDH1A1 | |
| SCHEMBL14496988 | 0.74 | TRPA1 (0.51) | TRPA1TSHRL3MBTL1MAPK1TDP1 | |
| SCHEMBL14496962 | 0.74 | TRPA1 (0.51) | TRPA1TSHRL3MBTL1MAPK1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8034822-B2 | Glucokinase activators | TAKEDA SAN DIEGO, INC. (US) | 2011-10-11 | — | — | US | disclosed |
| WO-2007104034-A2 | GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. (US) | 2007-09-13 | — | — | WO | disclosed |
| US-20070213349-A1 | GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. | 2007-09-13 | — | — | US | disclosed |
| US-20070213349-A1 | GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213349-A1 | GLUCOKINASE ACTIVATORS | GCK, GCKR, GALK1 | TRPA1 4472/4885TSHR 3402/4885L3MBTL1 4723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.